AMLN Amylin Pharmaceuticals, Inc. (MM)

SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) will be presenting at the BIOCOM Investor Conference on Thursday, November 1, 2007 at 9:30 a.m. PT in San Diego. Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals, will be providing a corporate overview. The live presentation will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate website, located at http://www.amylin.com/. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software. About Amylin Pharmaceuticals Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 1,800 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com/. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Alice Bahner Izzo, Executive Director of Corporate Affairs of Amylin Pharmaceuticals, Inc., +1-858-552-2200, x7272 Web site: http://www.amylin.com/

Copyright